Skip to Main Content

One in five women with breast cancer could be treated effectively with PARP inhibitors, according to a new study published Monday in Nature Medicine.

The previous school of thought was that PARP inhibitors, a class of drugs that interfere with DNA repair, only work in patients with certain mutations in the BRCA1 and BRCA2 genes. It’s estimated that between only 1 and 5 percent of women with breast cancer have these specific mutations.


These results suggest that PARP inhibitors, which are being studied and used in breast, ovarian, and prostate cancers, could have a much broader market than anticipated.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!